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Summrar A range of pure. monomeric porphyrins were synthesised and their localising capacities compared
to HpD and Hp at 6 h and 24 h post injection in the mouse C6 intracerebral glioma model as well as in
normal brain. skin. muscle, kidney. spleen, liver. lung and whole blood. The partition coefficients were
examined between PBS and 2-octanol over the pH range 7.4-6.6 and pH profiles were established. A
parabolic relationship was observed between log (porphyrin tumour concentration) at pH 7.4. With maximal
tumour localisation at log (partition coefficient). a. of approximately zero. Porphynns with side chains with
nett cationic character also exhibited an upward (parabolic) dependence on x for most tissues studied. with
maximal porphyrin localisation at iE of 0-0.5. In contrast. those porphyrins with nett anionic character
exhibited a downward (negative) parabolic trend for all eight tissues studied. with minimal porphyrin
localisation at x of approximately zero. Four porphyrins (4. 11. 12, 13) exhibited similar or better tumour
localisation than HpD. and two (11 and 12) offer promise as lead compounds for the design of improved
porphyrins for use in PDT.
Porphynrns are currently used in the photodynamic treatment
of tumours (Kaye et al.. 1988). Haematoporphyrin derivative
(HpD) is the most clinically used porphyrin and is the 'bench-
mark' compound to which all other prospective photothera-
peutic compounds are compared. The physicochemical
properties of the porphyrin (chemical structure, aggregation
states and hydrophobicity) are considered to be determinants
of localisation and photodynamic activity (Jori & Reddi.
1990). However. as a clinical drug HpD has many draw-
backs. one of which is skin photosensitisation that persists
after treatment. Furthermore, it is a controversial mixture of
compounds and the chemical structures responsible for
localisation and photodynamic effectiveness have yet to be
elucidated (Byrne et al., 1987; Dougherty, 1987; Kessel et al..
1987).
Cerebral gliomas are particularly suited to treatment by
photodynamic therapy (PDT). The current treatments such
as surgery. chemotherapy and radiotherapy are inadequate.
with the median survival for high grade glioblastoma mul-
tiforme being less than 1 year (Walker et al.. 1980). Cerebral
tumours are responsible for 2% of all cancer deaths (Kaye.
1989). The major reason for the encouraging results of PDT
with these tumours is the extent of localisation and retain-
ment of HpD that can be obtained within intracranial
tumours. Most treatments fail because of local recurrence of
the glioma. whereas PDT is a local treatment which
eliminates any such recurrence. Brain tumour to normal
brain ratios of HpD have been reported to be as high as 50: 1
(Hill et al., 1990). whilst animal tumours of the colon and
pancreas that have been treated with aluminium sulphonated
phthalocyanine or HpD have ratios of 2-3:1 between
tumour and the surrounding normal tissue (Bown. 1990). The
selective localisation in glioma is considered to be due to the
breakdown of the blood-brain barrier within the tumour
region - porphyrin can therefore be taken up by the tumour.
but is excluded from normal brain which retains an intact
blood-brain bamrer (Kaye et al., 1985).
In order to establish basic structure-activity relationships
for uptake of porphyrins in glioma. a range of pure
monomeric porphyrins were synthesised and the localisation
of these porphyrins was studied in the mouse C6 intracerebral
glioma model of Kaye et al. (1986). We present here the
distribution of monomeric porphynins (and for comparison
also HpD and Hp) between eight different tissues. as well as
the C6 glioma. and relate the tissue distributions to the
structure and partition coefficient of each porphyrin. These
results represent part of our continuing program to elucidate
the structural features required for the design of improved
tumour-localising porphyrins for use in PDT.
Materials and methods
Porphv rins
Haematoporphyrin derivative (HpD. 1) was obtained from
the Pharmacy Department. Queen Elizabeth Hospital
(Adelaide, South Adelaide) and was prepared according to
the method of Forbes et al. (1980). Haematophyrin (Hp. 2).
was obtained from Roussel UCLAF. Sydney. Australia and
was used as the starting material for all other porphyrin
derivates (3-13). Haematoporphyrin dimethyletherdimethyl
ester. 3. was synthesised using the method of Rimington et
al. (1987) as was haematoporphyrin diethylether (7). Por-
phyrin C (4) was synthesised according to the procedure of
Scourides et al. (1986). Porphyrin 13 was prepared using a
modification on the synthesis of 2.4-dif(m-methocycarbonyl-
methylthio)ethyl}deuteroporphyrin dimethyl ester by Slama
et al. (1975). The remaining porphyrins (5. 6, 8-12) are
original compounds and their synthesis. purification and
characterisation will be presented elsewhere. All porphyrins
were obtained in 80-95% yields. their purity established to
be >99% by analytical HPLC. and structures were confirmed
using IR. 'H and '3C NMR and FAB mass spectrometry.
Cells
The C6 glioma cell line was obtained from the Amenrcan
Type Culture Collection (Rockville. Maryland). Cells were
grown in RPMI 1644 medium (Commonwealth Serum
Laboratonres. Parkville, Australia) supplemented with 10%
foetal calf serum (Gibco, Helena Laboratories. Australia).
Animals and tumours
Adult male and female CBA mice, 5 to 8 weeks old, were
injected with C6 glioma cells suspended in a 1:1 (v v) solution
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of 2 x RPMI 1640 and 1% sea plaque agarose (FMC Corp..
Rockland, Maine) using the method established by Kaye et
al. (1985). This procedure results in the establishment of
discrete cerebral C6 tumours. The mice were anaesthetised by
methoxyfluorane inhalation. A 1 cm midline scalp incision
was made, and a Hamilton syringe (a 27 guage disposable
needle covered by a plastic sleeve) was inserted through the
coronal suture to a depth of 3 mm to the left of the midline.
A volume of 10 iLl of a tumour cell suspension (1 x 106 cells
10 l) was injected, the needle withdrawn after 30s. the hole
in the bone covered with sterile bone wax (Ethicon. Edin-
burgh. Scotland) and the wound then closed with wound
clips (Labco. Melbourne. Australia). The mice were used for
porphyrin tissue localisation studies 14 days post-inoculation
at which point the animals had developed tumours 4.1 mm in
diameter with a negligible amount of spontaneous necrosis
(Kave et al.. 1986.
Adninistration ofporphvrins
The photosensitisers were dissolved in 0.1 m HCI or 0.1 m
NaOH. as appropriate. and then adjusted to pH 7.4 with
Dulbecco's phosphate buffered saline (PBS) (Commonwealth
Serum Laboratories, Parkville. Australia) at a concentration
of 800 g m1 l. The solution was sterilised by passage
through a 0.2 gm filter (Schleicher & Schull. Germany). Since
the average weight of each mouse was 20 g. photosensitiser
solution (0.5 ml) was injected into each mouse to achieve an
overall administration dose of 20 mg kg-.
The porphyrin solution was injected via the tail vein and
the mice sacrificed 6 and 24 h post-administration. Samples
(20-80 mg) were excised from tumour, normal brain, skin.
muscle, kidney. spleen. liver and lung from each animal
together with 100;1l of whole blood. Three mice were used
for each porphyrin at each time point.
Tissue extraction procedure
The porphyrin content of the tissues was determined using
the method of Kessel and Cheng (1985) as modified by Hill
et al. (1990). Typically. the pre-weighed tissue was suspended
in 6 ml of 50 mm HEPES (Sigma). 10 mm cetyl trimethyl-
ammonium bromide (CTAB) (B.D.H. Pty. Ltd., Melbourne.
Australia), pH 7.4. and homogenised for 30 s with an Ystral
Type X1020 homogeniser (H.D. Scientific Supplies, Mel-
bourne, Australia). Triplicate 2 ml aliquots were removed,
and each was then extracted into 5 ml chloroform-methanol
(1:1. v v), thoroughly vortexed and centrifuged for 5 min at
2.000 g at room temperature in a bench centrifuge (Clements
GS200, Selby Scientific, Melbourne, Australia). The upper
phase and cell debris layer were discarded. The lower organic
phase was then evaporated under a stream of N2 gas. The
dried residue was then suspended in 2 ml of buffer (50 mm
HEPES, 10 mM CTAB, pH 7.4) and vortexed. This procedure
was followed for porphyrins 2-13. HpD (1) underwent a
hydrolysis step (Hill et al., 1990) to convert some poorly
fluorescing components of HpD to haematoporphyrin plus
hydroxyethylvinyldeuteroporphyrin, which exhibit enhanced
fluorescent yields (Kessel & Cheng, 1985). The HpD samples
were thus heated in sealed tubes in 0.5 mM HCI at 100°C for
30 min and then neutralised with 1 M NaOH. The absorb-
ance of all porphyrin solutions was determined prior to
fluorescence measurements. Absorbance was determined at
400 nm using a Beckman DU-65 spectrophotometer (Beck-
man Instruments Pty. Ltd., Melbourne, Australia) relative to
a control blank. The absorbance readings were necessary
since dilutions were sometimes required to prevent
concentration-dependent quenching of subsequent
fluorescence emission measurements. The porphyrin solution
was diluted appropriately (Hill et al., 1990) if the absorbance
in a 1 cm path length cell was greater than 0.15.
The fluorescence of the samples were determined using a
Perkin-Elmer LS-30 spectrofluorimeter (Perkin-Elmer Pty.
Ltd., Melbourne, Australia). The excitation and emission
wavelengths were established for each porphyrin. The total
porphyrin content in each sample was determined relative to
a standard curve of known porphyrin amounts prepared by
the same procedure. The assay was highly reproducible with
errors of less than 5% and resulted in >95% extraction of
HpD from the various tissues (Hill et al.. 1990). and >,90%
extraction of the remaining porphyrins presented in this
work. The addition of haemoglobin neither enhanced nor
quenched the fluorescence of the samples. provided the
absorbance measured at 400 nm in a I cm length cell was not
greater than 0.15 absorbance units.
Three mice were used for each of porphyrins 1-13 and
three aliquots of each tissue was assayed using this procedure.
the porphyrin level in the sample was then averaged and
expressed as micrograms of porphyrin gram of tissue (wet
weight) and for blood as microgram ml-' whole blood.
Partition coefficients
The partition coefficients of the porphyrins were evaluated at
different pH values (6.6-7.4) using the method of Kessel
(1977) for partitioning between 2-octanol and PBS. The two
solvents (1 ml of each) were vortexed for 1 min and the
phases resolved by centrifugation at 15.000 g for 5 min
(Biofuge A. Heraeus Sepatech. Foss Electric. Melbourne.
Australia). From each phase. 400fLI was sampled and mixed
with 2 Al of a 20 mg ml-' solution of porphyrnn in dimethyl-
formamide. The mixture was vortexed and the phases were
again separated by centrifugation (5 mmn). From each phase.
200 Al was removed and mixed with 25 Al of 1 M HCI and
200Al of acetone. The absorbance was measured at 550 nm
and the concentration of porphyrin determined in each phase
with reference to standard curves derived using the same
procedure. The partition coefficient was then calculated as
the ratio of porphyrin concentration in the organic:aqueous
phase.
Results
Biodistribution ofporphkrin analogues
The structures of the porphyrins studied are presented in
Figure 1. The porphyrins vary in structure. ranging from
tetra-anionic pendant side chains through to tetracationic
side chains. The distribution of porphyrins in mouse tissues
and blood is shown in Table I for time periods 6 h and 24 h
following a 20 mg kg-' intravenous injection. As expected
with such diverse porphyrin analogues, the biodistributions
exhibit a wide range of responses. The only constant feature
throughout was that the concentration of porphyrin was
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Table I Localisation studies of porphyrins 1- 13 in mouse tissues
Porphk rin Time (hy Twnour Brain Skin Muscle Kidney Spleen Liver Lung Blood
1 6 10.2 0.19 4.31 2.85 20.6 23.7 63.3 17.7 3.00
24 6.20 0.18 4.20 1.17 12.1 25.9 40.0 7.20 1.94
2 6 0.51 0.12 2.87 0.57 1.97 0.91 3.51 1.08 1.35
24 0.43 0.20 0.40 0.22 1.18 1.19 2.49 1.85 0.24
3 6 1.87 0.20 2.91 1.04 1.45 1.13 1.95 3.31 0.64
24 3.02 0.20 1.64 0.50 0.% 1.07 1.46 1.23 0.46
4 6 3.25 0.20 7.00 1.18 5.82 1.58 5.17 1.71 0.34
24 4.34 0.20 4.55 0.45 2.96 1.74 3.31 2.03 0.36
5 6 2.48 0.20 4.43 1.92 27.2 227 45.0 53.7 1.12
24 4.40 0.20 1.25 1.54 11.7 105 62.2 26.4 1.03
6 6 2.55 0.20 7.30 1.31 10.4 82.7 57.0 13.3 1.15
24 3.78 0.20 5.06 0.96 15.9 187 121 14.3 1.63
7 6 3.50 0.20 4.38 0.63 4.44 1.35 8.11 5.14 2.98
24 1.74 0.20 6.04 0.50 2.13 1.84 5.15 1.67 0.90
8 6 0.48 0.20 2.12 1.58 33.5 5.51 12.5 9.89 0.91
24 1.28 0.20 1.65 1.84 20.6 7.19 11.1 6.62 0.51
9 6 3.77 0.10 4.65 1.15 11.6 10.8 34.2 13.8 8.67
24 2.51 0.10 2.32 0.55 4.99 6.04 9.19 3.2 1.94
10 6 3.03 0.20 4.58 2.13 8.30 3.60 4.50 7.30 0.83
24 1.60 0.20 2.00 1.90 3.40 3.40 4.80 8.40 0.48
11 6 11.7 0.20 3.20 1.98 25.9 14.9 146 13.7 11.7
24 7.20 0.20 1.00 1.72 15.3 19.3 100 10.4 4.45
12 6 2.53 0.18 5.10 2.81 15.9 7.20 19.7 18.3 1.80
24 8.23 0.20 3.26 1.47 13.9 10.3 28.6 10.7 2.28
13 6 4.60 0.20 6.90 3.23 9.15 27.5 14.3 5.09 6.60
24 5.08 0.18 2.22 1.30 14.2 22.9 27.9 11.3 4.37
The porphyrin distribution in different tissues is expressed as ;ig g-' tissue wet weight except for blood
values which are expressed as fig ml-l of whole blood. The values reported are the mean of nine
measurements for each time point at each tissue. The standard deviation was typically ± 10% for most
tissues except those where lower porphyrin levels (e.g. brain) resulted in a standard deviation of ± 25%.
lowest in normal brain due to the exclusion ofporphynns by the blood-brain barrier.
Porphyrins 11 and 1 (HpD) showed significantly higher
tumour localising capacities (11.7 and 10.2 pgg-' respec-
tively) at 6h post injection compared to the other por- phyrins. The tumour to surrounding normal tissue (brain)
ratio was over 50 to 1 for these two compounds at this time.
At 24 h post injection the best tumour localisers were por- phyrins 1, 11 and 12. with tumour: normal brain ratios of
between 34: 1 and 41:1. Heamatoporphyrin (2) and porphyrin 8 were the poorest tumour localisers with maximal levels of
only 0.51 and 0.48 Lgg-' achieved corresponding to a ratio
of 2-2.5:1. The same result was seen at 24h post injection. The poryphyrins that exhibited significant tumour uptake between 6h and 24h were 3, 5, 6, 8 and 12. Porphyrin 12
showed a marked jump from 2.53 jigg-' at 6 h to 8.23 jgg-'
at 24 h. It was noted that these porphyrin had an overall
positive charge. The anionic porphyrins (1. 7 and 9) all
showed a decrease in concentration in tumour tissue with
increasing time.
In general, after 24 h the porphyrins accumulated at higher concentrations in the liver, spleen and kidneys. The excep- tions were porphyrins 3 and 4 which exhibited tumour to
other tissue ratios greater than 1, except for a similar level in
the skin for porphyrin 4. The values obtained for the lung have to be treated with some caution as they may have been
contaminated to some extent with blood during the tissue
extraction procedure. Lower levels were generally seen in
skin, blood and muscle with much lower levels in normal
brain. Biodistribution ofporphyrins 1, 8 and 11 are shown in
Figure 2a.
Partition coefficients
Partitioning of the porphyrins between 2-octanol and PBS at
pH 6.6, 6.8,7.0, 7.2 and 7.4 were determined at 20°C and the
partition coefficients are listed in Table II. The ranking. in
order of hydrophobicities, varied with pH due to the ionisa-
tion characteristics of the various pendant side chains. At
pH 7.4 porphyrin 13 was the most hydrophilic and porphyrin
8 was the most hydrophobic, whereas at pH 6.6 porphyrin 4
was the most hydrophilic and porphyrin 7 was the most
hydrophobic.
The porphyrins were resolvable into three classes depend-
ing on the nature of their pH profiles between pH 6.6-7.4:
increasing lipophilicity with decreasing pH (1, 2. 3. 6, 7. 11.
12 and 13); decreasing lipophilicity with decreasing pH (5. 8
and 10); and negligible change in lipophilicity over this pH
range (4). The changes in hydrophobicity with pH is marked
by the differences between porphyrins 7 and 9 and between 8
and 10. Porphyrins 7 and 9 (with carboxylic acid append-
ages) are the most hydrophobic porphyrins at pH 6.6. while
porphyrins 8 and 10 (with amidation of the carboxylic func-
tional group with N,N-dimethylethylenediamine) are the
most hydrophobic porphyrins at pH 7.4. The pH profiles of
three porphyrins (1, 8 and 11) are displayed in Figure 2b.
Tumour localisation
Figure 3 shows the relationship between partition coefficient
and porphyrin tumour localisation at 24 h. HpD (1) and Hp
(2) have also been included in this plot even though HpD
comprises a mixture of porphyrins (Byrne et al.. 1987:
Dougherty, 1987; Kessel et al., 1987) while Hp may also be
impure due to the presence of the secondary alcohol group
resulting in possible dehydration products. The data has been
plotted as log (tumour concentration) against log (partition
coefficient) (designated by x, Martin, 1981) and reveals a
general parabolic relationship, with maximal tumour localisa-
tion at ix of approxiimately zero (Figure 3). The partition
coefficients used for this analysis were those determined at
pH 7.4 since this represents an average physiological pH. Hp324 K.W. WOODBURN et al.
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Figure 2 Biodistribution and hydrophobicity of porphyrins 1, 8 and 11. a, The tissue distributions of porphynns were determined
6 h and 24 h post administration of 1, 8 and 11 to C6 bearing mice. The tissue concentrations shown are an average of nine
determinations (triplicate measurements of each tissue for each of three mice) and have been expressed as 1±g ofporphynrn per gram
of tissue wet weight, except for blood values which are expressed as 1tg of porphyrin per ml of whole blood. The error bars
represent the standard deviation of the nine measurements of each tissue. b, Dependence of partition coefficient (2-octanol:PBS
buffer) on pH.
(2) does not fit the parabolic trend and was excluded from
the regression analysis and this deviation may relate to the
effect of dehydration products. The parabolic trend is rather
broad, and implies that substantial tumour concentration
would occur for x in the approximate range -2 < x< + 1.
No other significant correlation was observed for any other
data at any time point or tissue class, and this is not un-
expected given the wide range of porphyrin structures
studied. Because of this structural diversity the porphyrins
were divided into two groups on the basis of the overall nett
charge of their pendant side chain groups being either
cationic or anionic. Porphyrins 2, 4, 7, 9 and 13 are anionic
porphyrins while 5, 6, 8, 10 and 12 are cationic porphyrins.
Only the tissue distribution data at 24 h post injection has
been subjected to more detailed analysis since complete tissue
localisation and equilibration may not have been achieved
after only 6 h.
a
175i
1U
1i0
50
5a.
-
CD
a
a
CD
co
Pl1
b
I~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
ft. - j_ .-
- E . --I
75ZPORPHYRINS FOR PHOTODYNAMIC THERAPY 325
Table II Dependence of partition coefficients on pH for porphynrns
1-13
Partition coefficient
Porphyrin pH6.6 pH 6.8 pH 7.0 pH 7.2 pH 7.4
1 4.69 2.54 1.25 0.66 0.34
2 10.9 4.96 .08 0.67 0.38
3 37.7 32.0 21.5 13.3 7.47
4 0.05 0.04 0.05 0.04 0.05
i 1.71 3.29 5.11 1.71 3.92
6 20.3 15.5 13.4 13.4 13.6
223 65.8 28.8 21.7 14.8
8 .556 10.5 15.7 41.9 44.8
9 157 135 112 38.8 12.5
10 7.05 11.5 19.4 24.1 43.2
11 78.9 10.8 4.58 2.18 0.99
12 6.74 4.74 2.37 1.34 0.81
13 0.23 0.17 0.09 0.03 0.01
The values listed are a mean of three determinations. with a
standard deviation of ± 50o.
Relationship oftissue distribution writh partition coefficient at
pH 7.4for porphvrins wvith cationic side chains
The dependence of tissue distribution for the catiomnc por-
phvnrns at 24 h post injection is shown in Figure 4 with
respect to x where the data was plotted as log (concentration
in each tissue) *s it. Normal brain was not considered as the
blood-brain bamrer is essentially impermeable to all por-
phvrins. No correlation was apparent for skin. muscle and
kidnev distributions at pH 7.4. Parabolic trends were
observed with all other tissue samples (tumour. spleen. liver.
lung and blood) with maximal tissue localisation at x in the
range 0-0.5 in all cases. The correlation coefficients for these
parabolic relationships were >0.8 except for blood (0.77).
Relationship of tissue distribution writh partition coefficient at
pH 7 4 for porphv rins wt-ith anionic side chains
The localisation of anionic porphyrins exhibited a parabolic
dependence of tissue concentration with for all tissues
(Figure 5). The unexpected feature was that in all tissues this
trend was that of a 'negative' parabola with minimal localisa-
tion at xi of approximately zero. This is in direct contrast to
the cationic porphvrins where a parabolic correlation was
observed. with maximal localisation at it of zero. The correla-
tion was significant for tissues (correlation coefficient >0.8)
and all tissues exhibited a correlation coefficient >0.7 except
skin (0.64). These correlations should still be treated with
some caution since thev are based on a limited data set.
Furthermore, the data set includes HpD ( =- 0.4) which is
not a pure species.
Discussion
The time points of 6 and 24 h post injection were chosen for
tissue localisation studies since Kaye et al. (1985) showed
that maximal uptake in tumour compared to normal brain
occurred between 6 and 24 h after i.v. administration of
HpD. The porphyrins selected for this study were pure.
monomeric compounds as compared to the clinically used
porphyrin mixture, HpD. and were synthesised as part of our
attempt to establish guidelines for the development of new
localisers and photosensitisers for PDT.
Other tissue localisation studies with HpD
The tissue distribution of HpD has been reported by many
groups in the past and has been reviewed by Henderson and
Bellnier (1989). For comparison to the present work, the
most relevant study was by Gomer and Dougherty (1979).
where the distribution was reported for a range of tissues
after i.p. injection of tritiated HpD in mice at a dose of
C
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Figure 3 Dependence of tumour localisation on partition
coefficient. The tumour concentration of porphxrins 1-13 was
determined 24 h after administration of 20 mg kg to C6 beanrng
mice. The partition coefficients (2-octanol:PBS buffer) were deter-
mined at pH 7.4. and plotted as xt (log of partition coefficient).
The continuous line represents the non-linear regression fit to 12
of the data points defining this trend (correlation coefficient of
0.86) and excluded the value for Hp (i = - 0.42).
1Omg kg-'. Given the different experimental conditions em-
ployed (i.v. injection and 20 mg kg- in the present study.
different tumour models etc.) the overall distributions were
remarkably similar (e.g. 4.1-5.3 gg in the tumour com-
pared to 6.2jgg` in the present study) and the biodistri-
bution ranking was also similar.
Reticuloendothelial localisation
The tissues such as the kidney. spleen and liver exhibited
higher concentrations than the tumour showing that the
porphyrins are not exclusively retained by tumour tissue.
Liver, spleen and kidney have shown generally high levels of
porphyrins in this study and are part of the reticuloendo-
thelial system and or function as transport systems for serum
proteins. Kessel (1986) reported that the distribution of por-
phyrins is directly associated with the number of LDL recep-
tors in those tissues (liver> kidney>lung> spleen) and this
was partially supported by the present results: liver levels
were greater than kidney concentrations for 12 of the 13
porphyrins; kidney>lung for nine of the 13: lung> spleen
for five of the 13. Tumour cells have an elevated number of
low density lipoprotein receptors (Maziere et al.. 1990) and
this may account in part for the specific uptake of certain
porphyrins into brain tumour compared to normal brain.
Structure-localisation relationship
Porphyrins 11 and 12 possess one side group which is iden-
tical (morpholino) whereas the other side group represents
opposite charge (anionic vs cationic). Both porphyrins exhibit
a partition coefficient of approximately one, and both are
good tumour localisers. This suggests that the morpholino
side group may have some role in defining the overall parti-
tion coefficient, and hence the resultant tumour localisation.
It should also be noted that both of these porphynins localise
to discrete subcellular organelles. and as a consequence may
exhibit more precise targeting of photosensitive sites. This
may account for their enhanced phototoxicity when com-
it326 K.W. WOODBURN et al.
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Fugwe 4 Relationship between tissue distribution and partition coefficient (pH 7.4) for porphyrins with nett cationic side chains
(porphyrins 5. 6. 8, 10 and 12). Correlation coefficients were 0.95 (tumour), 0.91 (spleen), 0.81 (liver), 0.92 (lung) and 0.77 (blood).
pared to similar anionic porphyrins (Woodburn et al., 1991).
Both of these porphyrins therefore possess the desired dual
characteristics of exhibiting good tumour localisation and
targeting crucial subcellular organelles, and therefore offer
good prospects as lead compounds for evaluation of other
monomeric porphyrins for use in PDT.
With respect to the localising ability of other porphyrins,
the tumour:skin ratio of 20:1 for uroporphyrin I suggests
that this compound may be a good candidate for PDT when
compared to a ratio of 2.5:1 (El-Far & Pimstone, 1986) and
1.5:1 (Table I) for HpD. However, uroporphyrin I was found
to be a poor photosensitiser both in vitro and in vivo (Nelson
et al., 1990). Good tumour localisation was exhibited by 11
and 12 with tumour:skin ratios of 7.2:1 and 2.5:1 respec-
tively and these porphyrins should therefore be tested for
PDT activity in vivo.
The reasons, or any theories, regarding the mechanism of
uptake of these porphyrins into the various tissues studied
cannot, as yet, be proposed since more extensive phamarco-
logical data needs to be acquired. Since the effectiveness of
any photosensitiser depends on its circulation and distribu-
tion properties, the interaction of the photosensitiser with
serum proteins (and in particular lipoproteins) should be
considered. The distribution of porphyrins among proteins is
generally thought to be dependent on chemical structure
(Jori, 1989) and it is for this reason that the tissue distribu-
tions of porphyrins is expected to be dependent upon their
hydrophobicity, and hence upon their partition coefficient.
Photosensitisers which exhibited an increase of lipophilicity
with decreasing pH have been shown to be retained more in
tumour tissue than those compounds which exhibit a
different trend (Moan et al., 1987), and this is consistent with
the tissue distributions observed in the present study (Figure
2a). HpD (1) and porphyrin 11 had significant concentration
levels in tumour and their pH profiles showed an increasing
lipophilicity with decreasing pH. Porphyrin 8 had negligible
concentration levels in tumour and exhibited a decrease in
lipophilicity with decreasing pH. The acidity of tumour tissue
(Thistlethewaite et al., 1985) is thought to render membranes
more porphyrin soluble (Thomas & Girotti, 1989 and Pottier,
1990) thus the establishment of the pH dependence of parti-
tion coefficient may be an important aid in viewing the
effectiveness of compounds to localise in tumours.
Based on the limited data set of porphyrins studied in this
work, there appeared to be a complementary nature of tissue
localisation between the cationic and anionic porphyrins used
in this study. At 24 h the anionic porphyrins displayed
minimal tissue uptake at x of approximately zero whereas the
cationic porphyrins displayed maximal tissue uptake at
similar x values.
Use in PDT
Although high concentrations of the porphyrins exist in liver,
kidney and spleen, the monomeric porphyrins 2-13 are still
good candidates for use in PDT, especially in relation to
intracranial tumours where the porphyrin is administered
prior to surgical debulking, and then the remaining tumour is
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irradiated with laser - in this instance there is little effect of
porphyrin localisation on other tissues since these tissues are
not directly irradiated and the only disadvantage is the
requirement for the patient to avoid sunlight for some time
after treatment (Kaye. 1989). Brain tissue is one of the most
transparent tissues (Muller & Wilson. 1987) and effective
tumour kill is therefore enhanced compared to other tissues
which display less light transparency.
Effect ofsubcellular localisation
The in vitro subcellular localisation sites of porphyrins 1-13
have previously been studied using confocal laser scanning
microscopy (Woodburn et al., 1991). It was generally found
that those porphyrins with overall cationic pendant side
chains were retained by the mitochondria whereas those with
a dominant anionic character localised in lysosomes. Intracel-
lular localisation sites are important when considering the
effects of phototoxicity (Woodburn et al., in press). The
porphyrins that localised in the mitochondria were the most
phototoxic. Those that localised in lysosomes were also
phototoxic and provide a good target site in in vivo situations
since photoinduced destruction may lead to release of hydro-
lytic enzymes and subsequent surrounding cell death.
Porphynins 11 and 12 showed good tumour localising
capacities at 24 h post injection compared to the surrounding
normal brain and are therefore good candidates for further
investigation for PDT of brain tumours. Both porphyrins
were found to be more phototoxic than HpD in an in vitro
model due to their possible targeting of lysosomes and
mitochondria localisation followed by uptake into lysosomes.
The question arises as to what is responsible for ultimate cell
and tissue death; concentration effects (porphyrin localising
capacity) or the targeting of specific intracellular localisation
sites. In vitro photonecrosis experiments are currently in pro-
gress to answer this fundamental question.
Conclusions
The best lead compounds for further studies of tumour
localising monomeric porphyrins for use in PDT are por-
phyrins 12 and (to a lesser extent) 11. Not only do these
compounds exhibit good tumour:normal brain distributions
with the present tumour model, they also possess highly
desirable subcellular localisation properties (11 lysosomes;
12. mitochondria then lysosomal engorgement), with greater
predicted phototoxicity than comparable anionic porphyrins.
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